The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma.
 
Paul G. Richardson
Consulting or Advisory Role - Genmab
Research Funding - Celgene; Millennium
 
Michel Attal
No Relationships to Disclose
 
Jesus San Miguel
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; CELGENE; Janssen-Cilag; MSD; Novartis; Takeda
 
Frank Campana
No Relationships to Disclose
 
Solenn Le-Guennec
Employment - Sanofi
 
Ai-Min Hui
Employment - Sanofi
 
Marie-Laure Risse
Employment - Sanofi
 
Kenneth Carl Anderson
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Millennium
Patents, Royalties, Other Intellectual Property - Acetylon Pharmaceuticals; C4 Therapeutics; Oncopep